A Flexible Open-Source Decision Model for Value Assessment of Biologic Treatment for Rheumatoid Arthritis

ObjectiveThe nature of model-based cost-effectiveness analysis can lead to disputes in the scientific community. We propose an iterative and collaborative approach to model development by presenting a flexible open-source simulation model for rheumatoid arthritis (RA), accessible to both technical and non-technical end-users.MethodsThe RA model is a discrete-time individual patient simulation with 6-month cycles. Model input parameters were estimated based on currently available evidence and treatment effects were obtained with Bayesian network meta-analysis techniques. The model contains 384 possible model structures informed by previously published models. The model consists of the following components: (i) modifiable R and C++ source code available in a GitHub repository; (ii) an R package to run the model for custom analyses; (iii) detailed model documentation; (iv) a web-based user interface for full control over the model without the need to be well-versed in the programming languages; and (v) a general audience web-application allowing those who are not experts in modeling or health economics to interact with the model and contribute to value assessment discussions.ResultsA primary function of the initial version of RA model is to help understand and quantify the impact of parameter uncertainty (with probabilistic sensitivity analysis), structural uncertainty (with multiple competing model structures), the decision framework (cost-effectiveness analysis or multi-criteria decision analysis), and perspective (healthcare or limited societal) on estimates of value.ConclusionIn order for a decision model to remain relevant over time it needs to evolve along with its supporting body of clinical evidence and scientific insight. Multiple clinical and methodological experts can modify or contribute to the RA model at any time due to its open-source nature.

[1]  Gianluca Baio,et al.  Probabilistic sensitivity analysis in health economics , 2015, Statistical methods in medical research.

[2]  J. Smolen,et al.  The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. , 2005, Clinical and experimental rheumatology.

[3]  M. Sculpher,et al.  Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. , 2005, Health economics.

[4]  Joseph A Hill.  United States Life Tables , 2013 .

[5]  T. Trikalinos,et al.  Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine. , 2016, JAMA.

[6]  Raveendhara R. Bannuru,et al.  2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis , 2016, Arthritis care & research.

[7]  Fernando Alarid-Escudero,et al.  An Overview of R in Health Decision Sciences , 2017, Medical decision making : an international journal of the Society for Medical Decision Making.

[8]  M. Prevoo,et al.  Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. , 1995, Arthritis and rheumatism.

[9]  Allan Wailoo,et al.  The relationship between EQ-5D, HAQ and pain in patients with rheumatoid arthritis , 2013, Rheumatology.

[10]  Gianluca Baio,et al.  Estimating the expected value of partial perfect information in health economic evaluations using integrated nested Laplace approximation , 2015, Statistics in medicine.

[11]  W. Dixon,et al.  A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries. , 2010, Seminars in arthritis and rheumatism.

[12]  G. Guyatt,et al.  Adverse effects of biologics: a network meta-analysis and Cochrane overview. , 2011, The Cochrane database of systematic reviews.

[13]  R. Gerber,et al.  An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis: Modeling the Cost of Treatment Strategies in the United States. , 2016, Journal of managed care & specialty pharmacy.

[14]  S. Wilson.  Methods for the economic evaluation of health care programmes , 1987 .

[15]  Christian Weiss,et al.  PROSIT Open Source Disease Models for Diabetes Mellitus , 2016, ICIMTH.

[16]  Adrian E. Raftery,et al.  Bayesian model averaging: a tutorial (with comments by M. Clyde, David Draper and E. I. George, and a rejoinder by the authors , 1999 .

[17]  J. Reif,et al.  The Insurance Value of Medical Innovation , 2014 .

[18]  D. M. van der Heijde,et al.  Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis , 2014, Annals of the rheumatic diseases.

[19]  J. Madan,et al.  An overview of models used in economic analyses of biologic therapies for arthritis--from current diversity to future consensus. , 2011, Rheumatology.

[20]  S. Russi,et al.  AB0157 Trex 1 mutation in the members of a family with systemic lupus erythematosus and antiphospholipid syndrome , 2017 .

[21]  P. Tugwell,et al.  A simplified disease activity index for rheumatoid arthritis for use in clinical practice. , 2003, Rheumatology.

[22]  M. Sculpher,et al.  Decision Modelling for Health Economic Evaluation , 2006 .

[23]  Hyon K. Choi,et al.  Predicting mortality in patients with rheumatoid arthritis. , 2003, Arthritis and rheumatism.

[24]  S. Paisley,et al.  Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review , 2016, Health technology assessment.

[25]  Charles King,et al.  2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis , 2016, Arthritis & rheumatology.

[26]  Jinoos Yazdany,et al.  Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice , 2012, Arthritis care & research.

[27]  A. Brennan,et al.  Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK. , 2004, Rheumatology.

[28]  G. Oster,et al.  Mortality Risk by Functional Status and Health-related Quality of Life in Patients with Rheumatoid Arthritis , 2012, The Journal of Rheumatology.

[29]  J. Fransen,et al.  Excess mortality emerges after 10 years in an inception cohort of early rheumatoid arthritis , 2010, Arthritis care & research.

[30]  Joshua T. Cohen,et al.  A Call for Open-Source Cost-Effectiveness Analysis , 2017, Annals of Internal Medicine.

[31]  T. Therneau,et al.  The widening mortality gap between rheumatoid arthritis patients and the general population. , 2007, Arthritis and rheumatism.

[32]  F. Wolfe,et al.  The loss of health status in rheumatoid arthritis and the effect of biologic therapy: a longitudinal observational study , 2010, Arthritis research & therapy.

[33]  Raveendhara R. Bannuru,et al.  American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis , 2015 .

[34]  Simon G Thompson,et al.  Structural and parameter uncertainty in Bayesian cost-effectiveness models , 2010, Journal of the Royal Statistical Society. Series C, Applied statistics.

[35]  Tanja Stamm,et al.  Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. , 2005, Arthritis and rheumatism.

[36]  R. Akehurst,et al.  Benefits, Challenges and Potential Strategies of Open Source Health Economic Models , 2016, PharmacoEconomics.

[37]  Alan Brennan,et al.  Biologic drugs for rheumatoid arthritis in the Medicare program: a cost-effectiveness analysis. , 2008, Arthritis and rheumatism.

[38]  Hawre Jalal,et al.  Linear Regression Metamodeling as a Tool to Summarize and Present Simulation Model Results , 2013, Medical decision making : an international journal of the Society for Medical Decision Making.

[39]  J. Coast,et al.  The impact of using different tariffs to value EQ-5D health state descriptions: an example from a study of acute cough/lower respiratory tract infections in seven countries , 2013, The European Journal of Health Economics.

[40]  Atlanta,et al.  Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. , 2008, Arthritis and rheumatism.

[41]  D. Meltzer,et al.  Theoretical Issues Relevant to the Economic Evaluation of Health Technologies , 2011 .

[42]  M. Uffmann,et al.  Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score , 2005, Arthritis research & therapy.

[43]  B. van Hout,et al.  Modelling the cost-effectiveness of combination therapy for early, rapidly progressing rheumatoid arthritis by simulating the reversible and irreversible effects of the disease , 2015, BMJ Open.

[44]  M. Stevenson,et al.  The Cost-effectiveness of Sequences of Biological Disease-modifying Antirheumatic Drug Treatment in England for Patients with Rheumatoid Arthritis Who Can Tolerate Methotrexate , 2017, The Journal of Rheumatology.

[45]  E. Arias.  United States Life Tables, 2011. , 2015, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.

[46]  H. Birnbaum,et al.  Societal cost of rheumatoid arthritis patients in the US , 2010, Current medical research and opinion.

[47]  Maarten J. IJzerman,et al.  Multiple Criteria Decision Analysis for Health Care Decision Making--An Introduction: Report 1 of the ISPOR MCDA Emerging Good Practices Task Force. , 2016, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[48]  Louis P Garrison,et al.  Toward a Broader Concept of Value: Identifying and Defining Elements for an Expanded Cost-Effectiveness Analysis. , 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[49]  J. Kremer,et al.  Thresholds in disease activity for switching biologics in rheumatoid arthritis patients: Experience from a large US cohort , 2011, Arthritis care & research.

[50]  A. Brennan,et al.  The Sheffield rheumatoid arthritis health economic model. , 2011, Rheumatology.

[51]  P. Vemer,et al.  AdViSHE: A Validation-Assessment Tool of Health-Economic Models for Decision Makers and Model Users , 2015, PharmacoEconomics.

[52]  G. Kobelt,et al.  The burden of rheumatoid arthritis and access to treatment: health burden and costs , 2007, The European Journal of Health Economics.

[53]  S. Gabriel,et al.  Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. , 2008, Arthritis and rheumatism.

[54]  K. Athanasakis,et al.  Cost-utility analysis of tocilizumab monotherapy in first line versus standard of care for the treatment of rheumatoid arthritis in Greece , 2015, Rheumatology International.

[55]  T. Huizinga,et al.  Tocilizumab in the Treatment of Rheumatoid Arthritis: A Cost-Effectiveness Analysis in the UK , 2014, PharmacoEconomics.

[56]  SP0024 Comorbidity in Rheumatic Diseases , 2013 .

[57]  F. Wolfe,et al.  Treatment and nontreatment predictors of health assessment questionnaire disability progression in rheumatoid arthritis: A longitudinal study of 18,485 patients , 2011, Arthritis care & research.

[58]  J. Piercy,et al.  Impact of rheumatoid arthritis on quality of life, work productivity and resource utilisation: an observational, cross-sectional study in Brazil. , 2013, Clinical and experimental rheumatology.

[59]  M. Dougados,et al.  Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis , 2017, Annals of the rheumatic diseases.

[60]  S. Sullivan,et al.  Economic evaluation of tocilizumab monotherapy compared to adalimumab monotherapy in the treatment of severe active rheumatoid arthritis. , 2015, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[61]  Mark Lunt,et al.  Health Assessment Questionnaire disability progression in early rheumatoid arthritis: Systematic review and analysis of two inception cohorts , 2014, Seminars in arthritis and rheumatism.

[62]  G. Perkins,et al.  Sepsis: the LightCycler SeptiFast Test MGRADE®, SepsiTest™ and IRIDICA BAC BSI assay for rapidly identifying bloodstream bacteria and fungi - a systematic review and economic evaluation. , 2016, Health technology assessment.

[63]  Adrian E. Raftery,et al.  Bayesian Model Averaging: A Tutorial , 2016 .

[64]  V. Strand,et al.  OP0064 Discontinuation of Biologic Therapy in Rheumatoid Arthritis (RA): Analysis from the Consortium of Rheumatology Researchers of North America (CORRONA) Database , 2013 .